<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27065870</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Milrinone in Enterovirus 71 Brain Stem Encephalitis.</ArticleTitle><Pagination><StartPage>82</StartPage><MedlinePgn>82</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">82</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2016.00082</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) was implicated in a widespread outbreak of hand-foot-and-mouth disease (HFMD) across the Asia Pacific area since 1997 and has also been reported sporadically in patients with brain stem encephalitis. Neurogenic shock with pulmonary edema (PE) is a fatal complication of EV71 infection. Among inotropic agents, milrinone is selected as a therapeutic agent for EV71- induced PE due to its immunopathogenesis. Milrinone is a type III phosphodiesterase inhibitor that has both inotropic and vasodilator effects. Its clinical efficacy has been shown by modulating inflammation, reducing sympathetic over-activity, and improving survival in patients with EV71-associated PE. Milrinone exhibits immunoregulatory and anti-inflammatory effects in the management of systemic inflammatory responses in severe EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shih-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityTainan, Taiwan; Department of Emergency Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung UniversityTainan, Taiwan; Center of Infectious Disease and Signaling Research, National Cheng Kung UniversityTainan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">brain stem encephalitis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">milrinone</Keyword><Keyword MajorTopicYN="N">pulmonary edema</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27065870</ArticleId><ArticleId IdType="pmc">PMC4809901</ArticleId><ArticleId IdType="doi">10.3389/fphar.2016.00082</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barin J. G., &#x10c;ih&#xe1;kov&#xe1; D. (2013). Control of inflammatory heart disease by CD4+ T cells. Ann. N. Y. Acad. Sci. 1285 80&#x2013;96. 10.1111/nyas.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12134</ArticleId><ArticleId IdType="pubmed">23692566</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton P., Garcia J., Kouatli A., Kitchen L., Zorka A., Lindsay C., et al. (1996). Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 109 1302&#x2013;1312. 10.1378/chest.109.5.1302</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.5.1302</ArticleId><ArticleId IdType="pubmed">8625683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J., Su Z., Shi Z., Zhou Y., Xu Z., Xu Z., et al. (2008). Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. Ann. Thorac. Surg. 86 882&#x2013;888. 10.1016/j.athoracsur.2008.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2008.05.014</ArticleId><ArticleId IdType="pubmed">18721577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L. Y., Lin T. Y., Huang Y. C., Tsao K. C., Shih S. R., Kuo M. L., et al. (1999). Comparison of enterovirus 71 and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr. Infect. Dis. J. 18 1092&#x2013;1096. 10.1097/00006454-199912000-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00013</ArticleId><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi C. Y., Khanh T. H., Thoa le P. K., Tseng F. C., Wang S. M., Thinh le Q., et al. (2013). Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit. Care. Med. 41 1754&#x2013;1760. 10.1097/CCM.0b013e31828a2a85</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2a85</ArticleId><ArticleId IdType="pubmed">23685637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D., Chen C. L., He Y. X., Zu Y., Cao D. Z., Wang G. B., et al. (2009). Changes of immune function in patients with enterovirus 71 infection. Chin. J. Pediatr. 47 829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">20078993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida N., Tomoeda H., Oda T., Tayama E., Chihara S., Kawara T., et al. (1999). Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann. Thorac. Surg. 68 1661&#x2013;1667. 10.1016/S0003-4975(99)00716-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(99)00716-X</ArticleId><ArticleId IdType="pubmed">10585039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E. R., Hsu K. H., Twu S. J., Chen K. T., Tsai S. F., et al. (1999). An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341 929&#x2013;935. 10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman T. M., Wernovsky G., Atz A. M., Kulik T. J., Nelson D. P., Chang A. C., et al. (2003). Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107 996&#x2013;1002. 10.1161/01.CIR.0000051365.81920.28</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000051365.81920.28</ArticleId><ArticleId IdType="pubmed">12600913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., Susa T., Tanaka T., Murakami W., Fukuta S., Okuda S., et al. (2012). Low-dose &#x3b2;-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ. J. 76 1646&#x2013;1653.</Citation><ArticleIdList><ArticleId IdType="pubmed">22481100</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y. T., Wang S. M., Wang J. R., Yu C. K., Liu C. C. (2015). Norepinephrine and epinephrine enhanced the infectivity of enterovirus 71. PLoS ONE 10:e0135154 10.1371/journal.pone.0135154</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135154</ArticleId><ArticleId IdType="pmc">PMC4529162</ArticleId><ArticleId IdType="pubmed">26252639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay C. A., Barton P., Lawless S., Kitchen L., Zorka A., Garcia J., et al. (1998). Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J. Pediatr. 132 329&#x2013;334. 10.1016/S0022-3476(98)70454-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(98)70454-8</ArticleId><ArticleId IdType="pubmed">9506650</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeilly R. G. (2014). Sepsis, venous return, and teleology. Med. Hypotheses 83 545&#x2013;548. 10.1016/j.mehy.2014.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2014.09.001</ArticleId><ArticleId IdType="pubmed">25245463</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer S., Gortner L., Brown K., Abdul-Khaliq H. (2011). The role of milrinone in children with cardiovascular compromise: review of the literature. Wien. Med. Wochenschr. 161 184&#x2013;191. 10.1007/s10354-011-0869-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10354-011-0869-7</ArticleId><ArticleId IdType="pubmed">21360291</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A. R., Willoughby D. A. (1995). The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101 387&#x2013;389. 10.1111/j.1365-2249.1995.tb03123.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.1995.tb03123.x</ArticleId><ArticleId IdType="pmc">PMC1553238</ArticleId><ArticleId IdType="pubmed">7664483</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli A., Ertmer C., Westphal M., Rehberg S., Kampmeier T., Ligges S., et al. (2013). Effect of heart rate control with esmolol on haemodynamic and clinical outcomes in patients with septic shock. JAMA 310 1683&#x2013;1691. 10.1001/jama.2013.278477</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.278477</ArticleId><ArticleId IdType="pubmed">24108526</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N. J., Lennette E. H., Ho H. H. (1974). An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129 304&#x2013;309. 10.1093/infdis/129.3.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittinger C. A., D&#xfc;nser M. W., Haller M., Ulmer H., Luckner G., Torgersen C., et al. (2008). Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit. Care 12 R99 10.1186/cc6976</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc6976</ArticleId><ArticleId IdType="pmc">PMC2575588</ArticleId><ArticleId IdType="pubmed">18680591</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipley J. B., Tolman D., Hastillo A., Hess M. L. (1996). Milrinone: basic and clinical pharmacology and acute and chronic management. Am. J. Med. Sci. 311 286&#x2013;291. 10.1016/S0002-9629(15)41723-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9629(15)41723-9</ArticleId><ArticleId IdType="pubmed">8659556</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczypka M., Obmi&#xf1;ska-Mrukowicz B. (2010). Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice. Pharmacol. Rep. 62 1148&#x2013;1158. 10.1016/S1734-1140(10)70377-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(10)70377-7</ArticleId><ArticleId IdType="pubmed">21273672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Chen I. C., Liao Y. T., Liu C. C. (2014). The clinical correlation of regulatory T cells and cyclic adenosine monophosphate in enterovirus 71 infection. PLoS ONE 9:e102025 10.1371/journal.pone.0102025</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0102025</ArticleId><ArticleId IdType="pmc">PMC4092122</ArticleId><ArticleId IdType="pubmed">25010330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Lei H. Y., Huang K. J., Wu J. M., Wang J. R., Yu C. K., et al. (2003). Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: the roles of cytokines and cellular immune activation in patients with pulmonary edema. J. Infect. Dis. 188 564&#x2013;570. 10.1086/376998</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Lei H. Y., Huang M. C., Wu J. M., Chen C. T., Wang J. N., et al. (2005). Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr. Pulmonol. 39 219&#x2013;223. 10.1002/ppul.20157</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.20157</ArticleId><ArticleId IdType="pubmed">15635619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Liu C. C. (2009). Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev. Anti. Infect. Ther. 7 735&#x2013;742. 10.1586/eri.09.45</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.09.45</ArticleId><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Liu C. C. (2014). Update of enterovirus 71: epidemiology, pathogenesis and vaccine. Exp. Rev. Anti. Infect. Ther. 12 447&#x2013;456. 10.1586/14787210.2014.895666</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2014.895666</ArticleId><ArticleId IdType="pubmed">24579906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M., Liu C. C., Tseng H. W., Wang J. R., Huang C. C., Chen Y. J., et al. (1999). Clinical spectrum of enterovirus 71 infection of children in southern Taiwan, with an emphasis on the neurological complications. Clin. Infect. Dis. 29 184&#x2013;190. 10.1086/520149</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessel D. L. (2001). Managing low cardiac output syndrome after congenital heart surgery. Crit. Care. Med. 29 S220&#x2013;S230. 10.1097/00003246-200110001-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200110001-00004</ArticleId><ArticleId IdType="pubmed">11593065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>